Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer
European Journal of Cancer2018Vol. 97, pp. 7–15
Citations Over TimeTop 10% of 2018 papers
Stefano Cavalieri, Federica Perrone, Rosalba Miceli, Paolo A. Ascierto, Laura D. Locati, Cristiana Bergamini, Roberta Granata, Salvatore Alfieri, Carlo Resteghini, Donata Galbiati, Adele Busico, Nicholas Paielli, Roberto Patuzzo, Andrea Maurichi, Gianfrancesco Gallino, Roberta Ruggeri, Luigi Mariani, Marco Palla, Lisa Licitra, Paolo Bossi
Related Papers
- → Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma(2011)272 cited
- → Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib(2010)29 cited
- → The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms(2018)9 cited
- → Comparison of response evaluation criteria in solid tumors (RECIST), European Association for the study of the liver (EASL) and modified RECIST criteria in evaluation of tumor response after transarteriai chemoembolization of primary liver cancer(2011)2 cited
- → Application of circulating tumor cells detection in chemotherapeutic efficacy evaluation of non-small cell lung cancer(2018)